N-(3-Aminopropyl)methacrylamide Hydrochloride>98.0%(HPLC)(T)5g

6-Fluorobenzo[d]isoxazole, 98%, 250mg

2-[4-(2,2-Dimethylpropanoyl)piperazin-1-yl]ethanol hydrochloride, 95.0%, 250mg

4-Bromo-2,5-dichlorobenzoic acid, 95.0%, 5g

Microliter syringe GASTIGHT® series 1700 Point type 2, 250 µl, 1725 RN, 1 piece

2,2'-Bibenzothiazoline>85.0%(T)5g

1-[3-(Trifluoromethyl)benzyl]hydrazine dihydrochloride, 97%, 100mg

2-(5-Chloro-1H-indol-3-yl)acetic acid, 95.0%, 1g

6-Bromo-3-chloropyrazine-2-carboxylic acid, 95%, 100mg

tert-Butyl (1-(6-bromopyridin-2-yl)cyclobutyl)carbamate, 95.0%, 250mg

5-Bromo-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzoic acid, 98%, 1g

2-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,2,3,4-tetrahydroisoquinoline, 98%, 1g

BIS(4-(DIPHENYLAMINO)PHENYL)METHANONE, 95%, 1g